http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2015234367-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_675da95446813f07e8e8f04cc9ab324a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate | 2015-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c762fe24afb89d587ca6358a3ef7d175 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4618c15bb09a2fc8ff6349c2ec93046b |
| publicationDate | 2017-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2015234367-A1 |
| titleOfInvention | Compositions and methods of use for cell targeted inhibitors of the cystic fibrosis transmembrane regulator associated ligand |
| abstract | Abstract The present invention describes peptide drugs that inhibit the interaction between cystic fibrosis-transmembrane regulator-associated ligand (CAL) and cystic fibrosis transmembrane regulator (CFTR) and other proteins in cystic fibrosis and other diseases. These invented drugs have been chemically optimized to impart solubility, stability, cell permeability, mucus penetration, intracellular targeting and sequestration, increased potency and non-immunogenicity, while conserving and imparting efficacy. This renders these compositions suitable for human use, which is exemplified by use in the treatment of cystic fibrosis. |
| priorityDate | 2015-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 276.